Navigating the complexities of groundbreaking treatments can create headwinds. With innovations like Pulsed Field Ablation (PFA) at the forefront, challenges such as financial uncertainties, regulatory shifts, and global adoption become paramount. Join us for an insightful discussion on how global partners address these challenges, focusing on safety & efficacy, financial impacts, and clinical differentiation in areas where baseline data is scarce. 

Background on PFA: Pulsed Field Ablation (PFA) is a groundbreaking nonthermal energy source that is rapidly transforming atrial fibrillation (AF) treatment, affecting up to 38 million people worldwide. Unlike traditional heat or cold methods, PFA uses high-voltage electrical fields in microseconds for precise cell necrosis, marking a significant advancement in cardiology. 

Guests: 
- Juliane Ray, Global Head of Medtech Strategy, Clarivate (Moderator) 
- Annette Boyle, Editor, BioWorld MedTech 
- Dee Chaudhary, Principal Commercial Strategy Consulting, Clarivate 
- Pankhil Ghandhi, Senior Team Lead, Medtech Insights, Clarivate 
- David Begley, MD, Clinical Director in Cardiology, Royal Papworth Hospital

Send us a message!

Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.